Abstract
Each year, approximately 100,000 patients transition to hemodialysis as a life-saving therapy for end-stage renal disease (ESRD) in the United States (US). While approximately 132.000 patients in Indonesia undergo hemodialysis. The current paradigm in the US and most developed countries is to initiate “full-dose” thrice-weekly treatment schedules following the current standard practice to achieve an adequate dialysis dose, and the Kidney Disease Outcomes Quality Initiative (KDOQI) guideline recommends thrice-weekly treatment in patients without residual kidney function (RKF).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
